- Home
- BWIN vs ZYME Comparison
BWIN vs ZYME Comparison
Compare BWIN & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BWIN | ZYME |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | United States | United States |
| Employees | 4116 | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | BWIN | ZYME |
|---|---|---|
| Price | $16.53 | $22.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $34.00 | $32.75 |
| AVG Volume (30 Days) | ★ 1.5M | 532.6K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $76,304,000.00 |
| Revenue This Year | $10.94 | $63.10 |
| Revenue Next Year | $27.38 | $93.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.38 |
| 52 Week Low | $15.88 | $9.03 |
| 52 Week High | $47.15 | $28.49 |
Technical Indicators
Market Signals| Indicator | BWIN | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 27.03 | 49.95 |
| Support Level | $15.88 | $22.64 |
| Resistance Level | $17.71 | $23.50 |
| Average True Range (ATR) | 1.37 | 0.87 |
| MACD | -0.19 | 0.13 |
| Stochastic Oscillator | 8.32 | 70.88 |
Price Performance
Historical ComparisonAbout BWIN The Baldwin Insurance Group Inc.
The Baldwin Insurance Group Inc is a United States-based insurance distribution firm. Its products include Business Insurance, Benefits Consulting, Reinsurance, Specialty MGA, Embedded Insurance., Personal insurance, etc.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.